2017 International Congress Archives - Page 54 of 155

2017 International Congress

June 4-8, 2017. Vancouver, BC.

Electrode Impedance as a marker for “on” and “off” states in a Deep Brain Stimulation cohort: A pilot study

W. Deeb, J. Shute, M. Okun (Gainesville, FL, USA)
Electronic stethoscope in the diagnosis of orthostatic tremor

J. Tashiro, H. Otsuka, M. Hirotani, S. Hamada, H. Soma, M. Nonaka, S. Honma, K. Hamada, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)
Electrophysiological markers for emotional and cognitive impairment in Parkinson’s disease

N. Dissanayaka, T. Au, A. Angwin, J. O'Sullivan, G. Byrne, P. Silburn, R. Marsh, G. Mellick, D. Copland (Brisbane, Australia)
Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease

P. Lingor, A. Leha, B. Michalke, M. Börger, M. Bähr, I. Zerr, F. Maass (Göttingen, Germany)
Elevated GM3 Plasma Concentration in Idiopathic Parkinson’s Disease: a Lipidomics Analysis

R. Alcalay, R. Chan, C. Liong, A. Perotte, B. Zhou, E. Shorr, K. Marder, U. Kang, C. Waters, O. Levy, Y. Xu, H. Shim, I. Pe'er, G. Di Paolo (New York, NY, USA)
Emergence of Non-motor Fluctuations with Reference to Motor Fluctuations in Parkinson’s Disease

A. Kim, Y. Kim, A. Kim, C.W. Shin, B. Jeon, H. Kim (Seoul, Republic of Korea)
EMG-US guided incobotulinum toxinA treatment of a cohort of musicians affected by upper limb focal dystonia

A. Castagna, M. Ramella, G. Giacobbi, P. Cecconi, R. Converti (Milano, Italy)
Emotion regulation and neuropsychological status in psychogenic subtypes.

B. Scott, A. Strutt, P. Lundberg-Love, A. Schmitt, J. Jankovic, D. Bowers (Gainesville, FL, USA)
End of Life Care in Parkinson’s Disease

S. Mole, S. Jackson (Exeter, United Kingdom)
Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)